Detection of abacavir hypersensitivity by ELISpot method

Inflammation and Allergy - Drug Targets

Volumn 11, Issue 3, 2012, Pages 227-234

  Esser, Stefan ^a   Jablonka, Robert ^a   Heinemann, Falko M ^a   Reuter, Stefan ^b   Jaeger, Hans ^c   von Krosigk, Ariane ^c   Schenk Westkamp, Pia ^a   Schadendorf, Dirk ^a   Horn, Peter A ^a   Lindemann, Monika ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c Diagnostik München   (Germany)

Author keywords

Abacavir; ELISpot; HIV; Human leukocyte antigen; Hypersensitivity reaction; Interferon production; Lymphocyte transformation test

Indexed keywords

ABACAVIR; HLA B ANTIGEN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL;

EID: 84860445748     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152812800392751     Document Type: Article

References (35)

1. Roujeau J.C. Immune mechanisms in drug allergy. Allergol. Int., 2006, 55, 27-33.
2. Heller, H.M. Adverse cutaneous drug reactions in patients with human immunodeficiency virus-1 infection. Clin. Dermatol., 2000, 18, 485-489.
3. Coopman, S.A.; Johnson, R.A.; Platt, R.; Stern, R.S. Cutaneous disease and drug reactions in HIV infection. N Eng. J. Med., 1993, 328, 1670-1674.
4. Lin, D.; Tucker, M.J.; Rieder, M.J. Increased adverse drug reactions to antimicrobials and anticonvulsants in patients with HIV infection. Ann. Pharmacother., 2006, 40, 1594-1601.
5. Pirmohamed, M.; Park, B.K. HIV and drug allergy. Curr. Opin. Allergy Clin. Immunol., 2001, 1, 311-316.
6. Vilar, F.J.; Naisbitt, D.J.; Park, B.K. Pirmohamed M. Mechanisms of drug hypersensitivity in HIV-infected patients: the role of the immune system. J. HIV Ther., 2003, 8, 42-47.
7. Esser, S. Side effects of antiretroviral therapy - skin manifestations. MMW Fortschr. Med., 2008, 150, 10-11. German.
8. Shear, N.H.; Milpied, B.; Bruynzeel, D.P.; Phillips, E.J. A review of drug patch testing and implications for HIV clinicians. AIDS, 2008, 22, 999-1007.
9. Hetherington, S.; McGuirk, S.; Powell, G.; Cutrell, A.; Naderer, O.; Spreen, B.; Lafon, S.; Pearce, G.; Steel, H. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther., 2001, 23, 1603-1614.
10. Orkin, C.; Wang, J.; Bergin, C.; Molina, J.M.; Lazzarin, A.; Cavassini, M.; Esser, S.; Gomez Sirvent, J.L.; Pearce, H. An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe. Pharmacogenet Genomics, 2010, 20, 307-314.
11. Hughes, A.R.; Mosteller, M.; Bansal, A.T.; Davies, K.; Haneline, S.A.; Lai, E.H.; Nangle, K.; Scott, T.; Spreen, W.R.; Warren, L.L.; Roses, A.D. Team CNAS. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics, 2004, 5, 203-211.
12. Phillips, E.J.; Wong, G.A.; Kaul, R.; Shahabi, K.; Nolan, D.A.; Knowles, S.R.; Martin, A.M.; Mallal, S.A.; Shear, N.H. Clinical and immunogenetic correlates of abacavir hypersensitivity. AIDS, 2005, 19, 979-981.
13. Mallal, S.; Nolan, D.; Witt, C.; Masel, G.; Martin, A.M.; Moore, C.; Sayer, D.; Castley, A.; Mamotte, C.; Maxwell, D.; James, I.; Christiansen, F.T. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet, 2002, 359, 727-732.
14. Mallal, S.; Phillips, E.; Carosi, G.; Molina, J.M.; Workman, C.; Tomazic, J.; Jagel-Guedes, E.; Rugina, S.; Kozyrev, O.; Cid, J.F.; Hay, P.; Nolan, D.; Hughes, S.; Hughes, A.; Ryan, S.; Fitch, N.; Thorborn, D.; Benbow, A.; Team, P-S. HLA-B*5701 screening for hypersensitivity to abacavir. N. Eng. J. Med., 2008, 358, 568-579.
15. Peyriere, H.; Guillemin, V.; Lotthe, A.; Baillat, V.; Fabre, J.; Favier, C.; Atoui, N.; Hansel, S.; Hillaire-Buys, D.; Reynes, J. Reasons for early abacavir discontinuation in HIV-infected patients. Annals of Pharmacotherapy, 2003, 37, 1392-1397.
16. Cutrell, A.G.; Hernandez, J.E.; Fleming, J.W.; Edwards, M.T.; Moore, M.A.; Brothers, C.H.; Scott, T.R. Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir. Ann Pharmacother., 2004, 38, 2171-2172.
17. Bonta, P.I.; Vermeulen, J.N.; Speelman, P.; Prins, J.M. Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative. AIDS, 2008, 22, 1522-1523.
18. Calza, L.; Rosseti, N.; Biagetti, C.; Pocaterra, D.; Colangeli, V.; Manfredi, R. Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative. Int. J. STD AIDS, 2009, 20, 276-277.
19. Rauch, A.; Nolan, D.; Martin, A.; McKinnon, E.; Almeida, C.; Mallal, S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis., 2006, 43, 99-102.
20. Reeves, I.; Churchill, D.; Fisher, M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity reactions. Antiviral Therapy, 2006, 11, L11-L11.
21. Zucman, D.; Truchis, P.; Majerholc, C.; Stegman, S.; Caillat-Zucman, S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune Defic. Syndr., 2007, 45, 1-3.
22. Antiretroviral therapy of HIV infection. German-Austrian guidelines (position in September 2008)]. Dtsch. Med. Wochenschr., 2009, 134(Suppl 1), S4-S15. German.
23. European AIDS Clinical Society (EACS) guidelines. http://www.europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/eacsguidelines-v6_english.pdf (Accessed on January 10, 2012).
24. New DHHS guidelines for antiretroviral therapy. AIDS Alert, 2010, 25, 21-24.
25. EMEA. Ziagen (abacavir sulfate) - Summary of product characteristics. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000252/WC500050343.pdf (Accessed on January 10, 2012).
26. Lindemann, M.; Böhmer, J.; Zabel, M.; Grosse-Wilde, H. ELISpot: a new tool for the detection of nickel sensitization. Clin. Exp. Allergy, 2003, 33, 992-998.
27. Lindemann, M.; Rietschel, F.; Zabel, M.; Grosse-Wilde, H. Detection of chromium allergy by cellular in vitro methods. Clin. Exp. Allergy, 2008, 38, 1468-1475.
28. Oudshoorn, M.; Horn, P.A.; Tilanus, M.; Yu, N. Typing of potential and selected donors for transplant: methodology and resolution. Tissue Antigens, 2007, 69(Suppl 1), 10-12.
29. Heinemann, F.M. HLA genotyping and antibody characterization using the Luminex (TM) multiplex technology. Trans. Med. Hemother., 2009, 36, 273-278.
30. Metz, C.E. Basic principles of ROC analysis. Seminars in Nuclear Medicine, 1978, 8, 283-298.
31. Lindemann, M.; Schuett, P.; Moritz, T.; Ottinger, H.D.; Opalka, B.; Seeber, S.; Nowrousian, M.R.; Grosse-Wilde, H. Cellular in vitro immune function in multiple myeloma patients after high-dose chemotherapy and autologous peripheral stem cell transplantation. Leukemia, 2005, 19, 490-492.
32. Müller, C.R.; Ehninger, G.; Goldmann, S.F. Gene and haplotype frequencies for the loci HLA-A, HLA-B, and HLA-DR based on over 13,000 german blood donors. Hum. Immunol., 2003, 64, 137-151.
33. Sabin, C.A.; Worm, S.W.; Weber, R.; Reiss, P.; El-Sadr, W.; Dabis, F.; De Wit, S.; Law, M.; Monforte, A.D.; Friis-Moller, N.; Kirk, O.; Pradier, C.; Weller, I.; Phillips, A.N.; Lundgren, J.D.; Grp, D.S. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet, 2008, 371, 1417-1426.
34. Brothers, C.H.; Hernandez, J.E.; Cutrell, A.G.; Curtis, L.; Ait-Khaled, M.; Bowlin, S.J.; Hughes, S.H.; Yeo, J.M.; Lapierre, D.H. Risk of myocardial infarction and abacavir therapy: no increased risk across 52 GlaxoSmithKline-sponsored clinical trials in adult subjects. J. Acquir. Immune Defic. Syndr., 2009, 51, 20-28.
35. Martin, A.M.; Nolan, D.; Gaudieri, S.; Almeida, C.A.; Nolan, R.; James, I.; Carvalho, F.; Phillips, E.; Christiansen, F.T.; Purcell, A.W.; McCluskey, J.; Mallal, S. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U S A, 2004, 101, 4180-4185.